RAMSAY SANTE :Refinancing of Senior Debt Facilities
16 Luglio 2024 - 5:45PM
UK Regulatory
RAMSAY SANTE :Refinancing of Senior Debt Facilities
PRESS RELEASE
Paris, 16 July 2024
Refinancing of Senior Debt
Facilities
- Ramsay Santé has
started today the Amend & Extend process for the refinancing of
its €1,650m Senior Facilities, including €100m RCF and €100m Capex
lines, to proactively extend its upcoming 2026-2027 debt
maturities.
- The closing of
this Amend & Extend process is subject to market
conditions.
- Such refinancing
would enable Ramsay Santé to further support the implementation of
its key initiatives as part of its “Yes We Care” strategy
plan.
- In the context
of this refinancing project, the purpose of this release is to
provide existing and potential lenders with unaudited financial
statements for the 9 month-period ending 31st March 2024
as well as key business trends and unaudited financial information
as of end of May 2024.
**********
- Over the 9-month
period ending 31st March 2024, revenues increased by
+6,9% up to €3,7bn, mainly supported by a dynamic organic growth.
EBITDA decreased by -1,2% to €445m despite higher activity, mainly
impacted by lower subsidies, and increased gap between tariff
increases and inflation of our cost base.
- Over the last
twelve-month (LTM) period ending May 31st 2024, activity
growth in our countries has been solid. Together with price
indexation and ongoing efficiency measures in a challenging
inflationary environment, this translates into revenue growth of
+7,0% and resilient EBITDA1 growth of +€8m (+1,3%)
compared to prior year LTM period ending 31st May 2023.
This also reflects an EBITDA growth of +€33m vs. LTM period ending
31st December 2023, and +€11m
vs. LTM period ending 31st March 2024.
- Pre-IFRS16 LTM
Net leverage ratio stands at 5.0x as of end of March 2024, and 4.9x
as of end of May 2024, down from 5.4x as of end of December
2023.
- Ramsay Santé has
maintained its actions enhancing its role as a preferred
coordinator of integrated care pathways and a key private provider
of hospital and primary care services in support of the French and
Nordics public healthcare sectors. It has resulted in a
4% increase in patient admissions in our acute care facilities over
the July 2023 - May 2024 period, compared to prior year
corresponding period.
- In France,
regarding the 2024 MSO tariff campaign and after several
iterations, the group will benefit, on top of the 0.3% tariff
increase starting in March 2024, from the removal of the CICE
cancellation coefficient, amounting to an additional 2.2%
equivalent of tariff increase starting from 1st July
2024, and of the financing of specific night and weekend shifts
measures.
- The Ramsay Santé
group has continued in the past months the deployment of its “Yes
We Care” strategic plan to offer integrated, quality, affordable
and proximity care to all patients, by increasing its portfolio of
imaging equipment, expanding its network of primary care centers
and rolling-out new digital solutions. One of the achievements for
this year was the acquisition on June 14th 2024 of the
Cosem primary care centres in Paris and other major cities in
France, handling more than 1 million patient consultations per
annum in general and specialised medicine, dental care, imaging and
pathology.
Pascal Roché, Chief Executive Officer of
Ramsay Santé, says:
« The refinancing of our senior debt
facility would allow Ramsay Santé to further secure its development
towards our strategic objective as a trusted partner of choice to
our patients, doctors, employees and payors as the preferred
provider and coordinator of care along the patient pathways. Ramsay
Santé and all its employees and medical community continue to serve
the healthcare sector and its patients in both France and the 3
Nordics countries despite the scarcity of resources and the
inflation burden. »
The Board of Directors approved this release of unaudited
financial statements for the 9-month period ending 31st
March 2024 (that are attached to this press release) as well as key
business trends and unaudited financial information as of end of
May 2024 at its meeting held on 15 July 2024.
About Ramsay Santé
Ramsay Santé is the leader in private hospitalisation and primary
care in Europe. The Group has 38,000 employees and works with
nearly 9,300 practitioners to treat more than 12 million patients
per year in its 465 facilities and 5 countries: France, Sweden,
Norway, Denmark and Italy. Ramsay Santé offers almost all medical
and surgical specialities in three domains: Medicine, Surgery,
Obstetrics (MSO), Follow-up Care and Rehabilitation (FCR) and
Mental Health.
Legally, Ramsay Santé is a mission-driven
company committed to constantly improving the health of all
patients through innovation. Wherever it operates, the Group
contributes to public health service missions and the healthcare
network. Through its actions and the constant dedication of its
teams, Ramsay Santé is committed to ensuring the entire patient
care journey, from prevention to follow-up care.
Every year, the group invests over 200 million
euros to support the evolution and diversity of care pathways, in
medical, hospital, digital, and administrative aspects. Through
this commitment, our Group enhances access to care for all, commits
to provides best-in-class healthcare, systematically engages in
dialogue with stakeholders and strives to protect the planet to
improve health.
Facebook: https://www.facebook.com/RamsaySante
Instagram: https://www.instagram.com/ramsaysante
Twitter: https://twitter.com/RamsaySante
LinkedIn: https://www.linkedin.com/company/ramsaysante
YouTube: https://www.youtube.com/c/RamsaySante
Code ISIN and Euronext Paris:
FR0000044471
Website:
www.ramsaysante.fr
Investor / Analyst
Relations
Press Relations
Clément
Lafaix Brigitte
Cachon
Tel. +33 1 87 86 21
52 Tel.
+33 1 87 86 22 11
clement.lafaix@ramsaysante.fr brigitte.cachon@ramsaysante.fr
|
UNAUDITED CONSOLIDATED STATEMENT OF COMPREHENSIVE
(LOSS)/INCOME |
|
(In millions of euros) |
From 1 July 2023 to
31 March 2024 |
From 1 July 2022 to
31 March 2023 |
|
REVENUE |
3,701.3 |
3,462.2 |
|
Personnel expenses and profit sharing |
(1,902.1) |
(1,847.4) |
|
Purchased consumables |
(800.2) |
(724.6) |
|
Other operating income and expenses |
(373.4) |
(268.0) |
|
Taxes and duties |
(106.9) |
(103.1) |
|
Rent |
(74.1) |
(69.1) |
|
EBITDA |
444.6 |
450.0 |
|
Depreciation and amortisation |
(307.6) |
(296.1) |
|
Current operating profit |
137.0 |
153.9 |
|
Restructuring costs |
(7.5) |
(8.8) |
|
Result of the management of real estate and financial assets |
12.5 |
32.2 |
|
Other non-current income and expenses |
5.0 |
23.4 |
|
Operating profit |
142.0 |
177.3 |
|
Cost of gross financial debt |
(88.9) |
(51.6) |
|
Income from cash and cash equivalents |
19.6 |
4.5 |
|
Financial interests related to the lease liabilities (IFRS16) |
(59.5) |
(55.7) |
|
Cost of net financial debt |
(128.8) |
(102.8) |
|
Other financial income |
1.4 |
10.0 |
|
Other financial expenses |
(22.1) |
(13.1) |
|
Other financial income and expenses |
(20.7) |
(3.1) |
|
Corporate income tax |
(1.4) |
(22.4) |
|
Share of net result of associates |
-- |
-- |
|
CONSOLIDATED NET (LOSS)/PROFIT |
(8.9) |
49.0 |
|
Income and expenses recognised directly in equity |
|
|
|
- Foreign exchange translation differences |
13.5 |
(34.5) |
|
- Actuarial gains and losses relating to post-employment
benefits |
(10.1) |
23.7 |
|
- Change in fair value of hedging instruments |
(8.1) |
6.6 |
|
- Other |
0.1 |
1.9 |
|
- Income tax effects on other comprehensive income |
1.7 |
(7.3) |
|
Results recognised directly in equity |
(2.9) |
(9.6) |
|
TOTAL COMPREHENSIVE (LOSS)/INCOME |
(11.8) |
39.4 |
|
RESULT ATTRIBUTABLE TO (in millions of euros) |
From 1 July 2023 to
31 March 2024 |
From 1 July 2022 to
31 March 2023 |
|
- Net income, Group share |
(20.6) |
39.3 |
|
- Non-controlling interests |
11.7 |
9.7 |
|
NET (LOSS)/INCOME |
(8.9) |
49.0 |
|
NET EARNINGS PER SHARE (in euros) |
(0.19) |
0.36 |
|
DILUTED NET EARNINGS PER SHARE (in euros) |
(0.19) |
0.36 |
|
TOTAL COMPREHENSIVE (LOSS)/INCOME ATTRIBUTABLE TO (In
millions of euros) |
From 1 July 2023 to
31 March 2024 |
From 1 July 2022 to
31 March 2023 |
|
- Comprehensive (loss)/income, Group share |
(23.5) |
29.7 |
|
- Non-controlling interests |
11.7 |
9.7 |
|
TOTAL COMPREHENSIVE (LOSS)/INCOME |
(11.8) |
39.4 |
|
UNAUDITED CONSOLIDATED BALANCE SHEET - ASSETS |
|
(In millions of euros) |
31-03-2024 |
30-06-2023 |
|
Goodwill |
2,075.5 |
2,062.7 |
|
Other intangible assets |
211.1 |
213.8 |
|
Property, plant and equipment |
993.8 |
991.2 |
|
Right of use (IFRS16) |
2,015.8 |
2,047.1 |
|
Investments in associates |
0.2 |
0.2 |
|
Other non-current financial assets |
148.3 |
170.2 |
|
Deferred tax assets |
84.0 |
106.4 |
|
NON-CURRENT ASSETS |
5,528.7 |
5,591.6 |
|
Inventories |
121.0 |
118.2 |
|
Trade and other operating receivables |
715.3 |
538.6 |
|
Other current assets |
388.8 |
329.0 |
|
Current tax assets |
9.8 |
17.5 |
|
Current financial assets |
25.9 |
10.7 |
|
Cash and cash equivalents |
215.7 |
352.2 |
|
CURRENT ASSETS |
1,476.5 |
1,366.2 |
|
TOTAL ASSETS |
7,005.2 |
6,957.8 |
|
UNAUDITED CONSOLIDATED BALANCE SHEET – LIABILITIES AND
EQUITY |
|
(In millions of euros) |
31-03-2024 |
30-06-2023 |
|
Share capital |
82.7 |
82.7 |
|
Share premium |
611.2 |
611.2 |
|
Consolidated reserves |
549.1 |
502.6 |
|
Net income. Group share |
(20.6) |
49.4 |
|
Equity. group share |
1,222.4 |
1,245.9 |
|
Non-controlling interests |
34.3 |
31.0 |
|
TOTAL EQUITY |
1,256.7 |
1,276.9 |
|
Borrowings and financial debt |
1,876.8 |
1,893.8 |
|
Debt on commitment to purchase minority interests |
25.5 |
46.3 |
|
Non-current lease liability (IFRS16) |
1,899.2 |
1,928.0 |
|
Provisions for post-employment benefits |
111.6 |
105.4 |
|
Non-current provisions |
146.9 |
155.3 |
|
Other non-current liabilities |
9.2 |
6.7 |
|
Deferred tax liabilities |
17.8 |
52.8 |
|
NON-CURRENT LIABILITIES |
4,087.0 |
4,188.3 |
|
Current provisions |
33.9 |
39.9 |
|
Trade and other accounts payable |
503.6 |
471.9 |
|
Other current liabilities |
824.9 |
699.6 |
|
Current tax liabilities |
3.0 |
1.6 |
|
Current financial debts |
60.9 |
58.8 |
|
Debt on commitment to purchase minority interests |
7.1 |
7.3 |
|
Current lease liability (IFRS16) |
228.1 |
213.5 |
|
CURRENT LIABILITIES |
1,661.5 |
1,492.6 |
|
TOTAL EQUITY AND LIABILITIES |
7,005.2 |
6,957.8 |
|
UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN
EQUITY |
|
(In millions of euros) |
SHARE CAPITAL |
SHARE PREMIUM |
RESERVES |
RESULTS DIRECTLY RECORDED IN EQUITY |
TOTAL COMPREHENSIVE INCOME FOR THE YEAR |
EQUITY, GROUP SHARE |
NON-CONTROLLING INTEREST |
SHAREHOLDERS’ EQUITY |
|
Equity at 30 June 2023 |
82.7 |
611.2 |
566.2 |
(63.6) |
49.4 |
1,245.9 |
31.0 |
1,276.9 |
|
Capital increase (after deduction of issue costs net of tax) |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|
Treasury shares |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|
Stock options and free shares |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
|
Prior year result to be allocated |
-- |
-- |
49.4 |
-- |
(49.4) |
-- |
-- |
-- |
|
Dividend distribution |
-- |
-- |
-- |
-- |
-- |
-- |
(9.0) |
(9.0) |
|
Change in scope of consolidation |
-- |
-- |
-- |
-- |
-- |
-- |
0.6 |
0.6 |
|
Total comprehensive income for the year |
-- |
-- |
-- |
(2.9) |
(20.6) |
(23.5) |
11.7 |
(11.8) |
|
Equity at 31 March 2024 |
82.7 |
611.2 |
615.6 |
(66.5) |
(20.6) |
1,222.4 |
34.3 |
1,256.7 |
|
UNAUDITED STATEMENT OF INCOME AND EXPENSE RECOGNISED
DIRECTLY IN EQUITY |
|
(In millions of euros) |
30-06-2023 |
Income and expenses 2023 /2024 |
31-03-2024 |
|
Foreign exchange translation differences |
(60.8) |
10.9 |
(49.9) |
|
Actuarial gains and losses relating to post-employment
benefits |
(8.3) |
(7.9) |
(16.2) |
|
Change in fair value of hedging instruments |
2.7 |
(6.0) |
(3.3) |
|
Other |
2.8 |
0.1 |
2.9 |
|
Income and expenses recognised directly in equity |
(63.6) |
(2.9) |
(66.5) |
|
UNAUDITED CONSOLIDATED STATEMENT OF CASH
FLOWS |
|
(In millions of euros) |
From 1 July 2023 to
31 March 2024 |
From 1 July 2022 to
31 March 2023 |
|
Net result of the consolidated group |
(8.9) |
49.0 |
|
Depreciation and amortisation |
307.6 |
296.1 |
|
Other non-current income and expenses |
(5.0) |
(23.4) |
|
Share of net result of associates |
-- |
-- |
|
Other financial income and expenses |
20.7 |
3.1 |
|
Financial interest related to the lease liability (IFRS16) |
59.5 |
55.7 |
|
Cost of net financial debt excluding financial interest related to
lease liability |
69.3 |
47.1 |
|
Income tax |
1.4 |
22.4 |
|
EBITDA |
444.6 |
450.0 |
|
Non-cash items relating to recognition and reversal of provisions
(non-cash transactions) |
(11.6) |
2.0 |
|
Other non-current income and expenses paid |
(9.7) |
(4.3) |
|
Change in other non-current assets and liabilities |
(16.1) |
(26.2) |
|
Cash flow from operations before cost of net financial debt
and tax |
407.2 |
421.5 |
|
Income tax paid |
0.6 |
(22.2) |
|
Change in working capital requirements |
(76.0) |
(62.3) |
|
NET CASH FLOWS FROM OPERATING ACTIVITIES: (A) |
331.8 |
337.0 |
|
Investment in tangible and intangible assets |
(125.6) |
(133.9) |
|
Disposal of tangible and intangible assets |
1.2 |
0.5 |
|
Acquisition of entities |
(16.1) |
(13.1) |
|
Disposal of entities |
1.3 |
1.1 |
|
Dividends received from non-consolidated companies |
0.1 |
0.3 |
|
NET CASH USED IN INVESTING ACTIVITIES: (B) |
139.1 |
145.1 |
|
Capital increase and share premium increases: (a) |
|
-- |
|
Capital increase of subsidiaries subscribed by third parties
(b) |
|
0.5 |
|
Dividends paid to minority shareholders of consolidated companies:
(c) |
(9.0) |
(6.9) |
|
Interest paid: (d) |
(88.9) |
(51.6) |
|
Financial income received and other financial expenses paid:
(e) |
19.7 |
(1.8) |
|
Financial interest related to lease liability (IFRS16): (f) |
(59.5) |
(55.7) |
|
Debt issue costs: (g) |
|
-- |
|
Cash flow before change in borrowings: (h)
= (A+B+a+b+c+d+e+f+g) |
55.0 |
76.4 |
|
Increase in borrowings: (i) |
7.7 |
191.3 |
|
Repayment of borrowings: (j) |
(33.0) |
9.5 |
|
Decrease in lease liability (IFRS16): (k) |
(169.5) |
(161.8) |
|
NET CASH USED IN FINANCING ACTIVITIES: (C) = a + b + c + d
+ e + f + i + j + k |
(332.5) |
(76.5) |
|
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS: ( A +
B + C ) |
(139.8) |
115.4 |
|
Foreign exchange translation differences on cash and cash
equivalents held |
3.3 |
(8.1) |
|
Cash and cash equivalents at beginning of year |
352.2 |
132.5 |
|
Cash and cash equivalents at end of year |
215.7 |
239.8 |
|
Net indebtedness at beginning of year |
3,670.0 |
3,709.9 |
|
Cash flow before change in borrowings: (h) |
(55.0) |
(76.4) |
|
Capitalisation of loan issue costs |
1.5 |
1.5 |
|
Fair value of financial hedging instruments |
17.8 |
(10.0) |
|
Changes in scope of consolidation and other |
1.9 |
(45.8) |
|
Lease liability (IFRS16) |
152.8 |
178.1 |
|
Net indebtedness at end of year |
3,789.0 |
3,757.3 |
1 EBITDA before non-recurring income and expenses
- Ramsay Santé - Refinancing of senior Debt facilities - July 16
2024
Grafico Azioni Ramsay Generale De Sante (EU:GDS)
Storico
Da Dic 2024 a Dic 2024
Grafico Azioni Ramsay Generale De Sante (EU:GDS)
Storico
Da Dic 2023 a Dic 2024
